Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RARB | P10826 | 4/20 | 0.63 |
| ▸ | RAB9A | P51151 | 5/20 | 0.63 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.63 |
| ▸ | NPC1 | O15118 | 3/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.63 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.60 |
| ▸ | MAPT | P10636 | 3/20 | 0.60 |
| ▸ | HPGD | P15428 | 3/20 | 0.60 |
| ▸ | MEN1 | O00255 | 2/20 | 0.60 |
| ▸ | USP2 | O75604 | 2/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.60 |
| ▸ | GAA | P10253 | 1/20 | 0.60 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.56 |
| ▸ | CASP3 | P42574 | 1/20 | 0.52 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.52 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.52 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9436035 | 1.00 | RARB (0.63) | RARBRAB9AKDM4ENPC1SMN1; SMN2 | |
| SCHEMBL9636338 | 1.00 | RARB (0.63) | RARBRAB9AKDM4ENPC1SMN1; SMN2 | |
| SCHEMBL7907379 | 1.00 | RARB (0.63) | RARBRAB9AKDM4ENPC1SMN1; SMN2 | |
| SCHEMBL13029249 | 1.00 | RARB (0.63) | RARBRAB9AKDM4ENPC1SMN1; SMN2 | |
| SCHEMBL10342131 | 1.00 | RARB (0.63) | RARBRAB9AKDM4ENPC1SMN1; SMN2 | |
| SCHEMBL9241350 | 1.00 | RARB (0.63) | RARBRAB9AKDM4ENPC1SMN1; SMN2 | |
| SCHEMBL7910730 | 1.00 | RARB (0.63) | RARBRAB9AKDM4ENPC1SMN1; SMN2 | |
| SCHEMBL8961773 | 1.00 | RARB (0.63) | RARBRAB9AKDM4ENPC1SMN1; SMN2 | |
| SCHEMBL7121080 | 1.00 | RARB (0.63) | RARBRAB9AKDM4ENPC1SMN1; SMN2 | |
| SCHEMBL4815333 | 1.00 | RARB (0.63) | RARBRAB9AKDM4ENPC1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 178 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5876626-A | HIGH SPEED SWITCHING | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1999-03-02 | — | — | US | claimed |
| US-8956705-B2 | Ferroelectric liquid crystal (FLC) polymers | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2015-02-17 | — | — | US | disclosed |
| US-8778223-B2 | Liquid crystals having cyclohexyl core structures and fluorinated tails | LC VISION, LLC (US) | 2014-07-15 | — | — | US | disclosed |
| US-20120326083-A1 | LIQUID CRYSTALS HAVING CYCLOHEXYL CORE STRUCTURES AND FLUORINATED TAILS | LC VISION, LLC | 2012-12-27 | — | — | US | disclosed |
| US-20100220279-A1 | FERROELECTRIC LIQUID CRYSTAL (FLC) POLYMERS | NATIONAL SCIENCE FOUNDATION | 2010-09-02 | — | — | US | disclosed |
| WO-2010088333-A2 | FERROELECTRIC LIQUID CRYSTAL (FLC) POLYMERS | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2010-08-05 | — | — | WO | disclosed |
| US-7195719-B1 | High polarization ferroelectric liquid crystal compositions | DISPLAYTECH, INC. (US) | 2007-03-27 | — | — | US | disclosed |
| EP-0639189-B1 | PYRIDYLPYRIMIDINES, A METHOD OF PREPARING THEM, AND THEIR USE IN LIQUID-CRYSTAL MIXTURES | AVENTIS RES & TECH GMBH & CO (DE) | 2003-02-19 | — | — | EP | disclosed |
| EP-0799830-B1 | Imidazothiazol derivatives as components of liquid crystalline mixtures | ROLIC AG (CH) | 2002-05-29 | — | — | EP | disclosed |
| EP-1160242-A1 | Aromatic fatty acid esters | Rolic AG (CH) | 2001-12-05 | — | — | EP | disclosed |
| WO-1986006401-A1 | SMECTIC LIQUID CRYSTALLINE PHASES | MERCK Patent Gesellschaft mit beschränkter Haftung (DE) | 1986-11-06 | — | — | WO | disclosed |
| WO-1986006373-A1 | NITROGEN-CONTAINING HETEROCYCLES | MERCK Patent Gesellschaft mit beschränkter Haftung (DE) | 1986-11-06 | — | — | WO | disclosed |
| EP-0199004-A1 | Pyrimidine derivatives | MERCK PATENT GmbH (DE) | 1986-10-29 | — | — | EP | disclosed |
| WO-1986005799-A1 | LIQUID CRYSTAL PHASE | MERCK Patent Gesellschaft mit beschränkter Haftung (DE) | 1986-10-09 | — | — | WO | disclosed |
| WO-1986005484-A1 | CYCLOHEXANE DERIVATIVES | MERCK Patent Gesellschaft mit beschränkter Haftung (DE) | 1986-09-25 | — | — | WO | disclosed |
| WO-1986004328-A1 | TERPENOID DERIVATIVES AND LIQUID CRYSTAL MATERIALS AND DEVICES CONTAINING THEM | THE SECRETARY OF STATE FOR DEFENCE IN HER BRITANNI (GB) | 1986-07-31 | — | — | WO | disclosed |
| WO-1986004081-A1 | LIQUID CRYSTALLINE PHASES | MERCK Patent Gesellschaft mit beschränkter Haftung (DE) | 1986-07-17 | — | — | WO | disclosed |
| EP-0174541-A1 | Electrooptic display element | MERCK PATENT GmbH (DE) | 1986-03-19 | — | — | EP | disclosed |
| EP-0152808-A2 | Nitrogen containing heterocycles | MERCK PATENT GmbH (DE) | 1985-08-28 | — | — | EP | disclosed |
| EP-0151446-A2 | Liquid crystal phase | MERCK PATENT GmbH (DE) | 1985-08-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120326083-A1 | LIQUID CRYSTALS HAVING CYCLOHEXYL CORE STRUCTURES AND FLUORINATED TAILS | Q6ZSR9, CRACR2A, RCC1 | RARB 3797/4885RAB9A 2644/4885KDM4E 759/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.